RDY 57.04 Dr. Reddy's Laboratories Ltd $RDY Hit a 52 week high of 57.13 Closing the day 09:44 at 57.04 +0.26 +0.46% With a day low of 56.88 and a total volume of 11,329.
RDY Recent Posts: http://investorshangout.com/Dr-Reddys-Laborat...RDY-52499/
RDY Dr. Reddy's Laboratories Ltd Recent Headline News
Dr Reddys Laboratories Up 13.0% Since SmarTrend Uptrend Call (RDY)
Comtex SmarTrend(R) - 1 hr 15 mins ago
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on October 23rd, 2014 at $50.46. In approximately 4 weeks, Dr Reddys Laboratories has returned 13.03% as of today's recent price of $57.03.
RDY: 56.98 (+0.20)
Dr. Reddy's Announces the Launch of Over-the-Counter Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets
Business Wire - 2 hrs 30 mins ago
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg, a bioequivalent generic version of Allegra-D(R) 12 Hour Allergy & Congestion, in the U.S. market on November 18, 2014. Dr. Reddy's ANDA is approved by the United States Food & Drug Administration (USFDA).
RDY: 56.98 (+0.20)
Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 3:30PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) and partner Takeda Pharmaceutical Company Limited filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Dr. Reddy's Laboratories (RDY).
JAZZ: 172.00 (+1.05), ARQL: 1.26 (-0.02), SCMP: 11.48 (-0.24), RDY: 56.98 (+0.20)
Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST
ENDP: 69.37 (+0.36), RDY: 56.98 (+0.20)
Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 4:20PM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, down 17% from the year-ago quarter.
MNK: 86.84 (+0.86), ACT: 264.02 (-2.02), MYL: 55.81 (+0.13), RDY: 56.98 (+0.20)
Dr. Reddy's Laboratories (RDY) Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 12:50AM CDT
RDY: 56.98 (+0.20)
Dr. Reddys ups revenues 7% in FQ2
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 12:43PM CDT
RDY: 56.98 (+0.20)
Dr. Reddy's FQ2 EPS of $0.54
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 5:55AM CDT
RDY: 56.98 (+0.20)
Dr. Reddy's Q2 and H1 FY15 Financial Results
Business Wire - Wed Oct 29, 5:41AM CDT
--Q2 FY15 EBITDA at Rs. 8.7 billion (24% of the revenues)
RDY: 56.98 (+0.20)
Dr. Reddy's Announces the Launch of Sirolimus Tablets, 1 mg and 2 mg
Business Wire - Tue Oct 28, 12:24PM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Sirolimus Tablets 1 mg and 2 mg, a therapeutic equivalent generic version of RAPAMUNE(R) (Sirolimus) tablets in the US market on October 27, 2014, following the approval by the United States Food & Drug Administration (USFDA).
RDY: 56.98 (+0.20)
Dr. Reddy's reports on October 29
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 6:09AM CDT
RDY: 56.98 (+0.20)
Dr. Reddy's to Release Q2 FY15 Results on October 29, 2014
Business Wire - Fri Oct 17, 4:38AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Second Quarter ended September 30, 2014 on Wednesday, October 29, 2014 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 56.98 (+0.20)
Sucampo Enters into Settlement Agreement for Amitiza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:50PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) has entered into a settlement agreement with Anchen and Par regarding a patent litigation related to Sucampo's Amitiza.
LCI: 47.15 (+0.31), SCMP: 11.49 (-0.23), RDY: 56.98 (+0.20)
Dr Reddys Laboratories Has Returned 20.3% Since SmarTrend Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 08, 4:57PM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 20.35% as of today's recent price of $49.92.
RDY: 56.98 (+0.20)
Dr Reddys Laboratories Shares Up 26.0% Since SmarTrend's Buy Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 01, 11:03AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 25.96% as of today's recent price of $52.25.
RDY: 56.98 (+0.20)
Dr. Reddy's (RDY) Generic Xopenex Launched in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:19PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) has launched its generic version of Sunovion Pharmaceuticals Inc.???s Xopenex in the U.S.
SUPN: 9.05 (+0.26), MYL: 55.81 (+0.13), TEVA: 57.26 (+0.01), RDY: 56.98 (+0.20)
Uptrend Call Working As Dr Reddys Laboratories Stock Rises 26.6% (RDY)
Comtex SmarTrend(R) - Wed Sep 24, 9:40AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 26.59% as of today's recent price of $52.51.
RDY: 56.98 (+0.20)
Dr. Reddy's unveils US FDA approved Levalbuterol Inhalation Solution, USP for oral inhalation only
M2 - Wed Sep 24, 7:03AM CDT
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Wednesday the market availability of Levalbuterol Inhalation Solution, USP 0.31 mg /3 ml, 0.63 mg /3 ml, 1.25 mg / 3 ml Unit-Dose Vials in the US.
RDY: 56.98 (+0.20)
Dr. Reddy's Announces the Launch of LEVALBUTEROL INHALATION SOLUTION, USP
Business Wire - Wed Sep 24, 2:27AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX(R) (levalbuterol hydrochloride) inhalation solution in the US market on September 23, 2014, approved by the United States Food & Drug Administration (USFDA).
RDY: 56.98 (+0.20)
RDY Recent Posts: http://investorshangout.com/Dr-Reddys-Laborat...RDY-52499/
RDY Dr. Reddy's Laboratories Ltd Recent Headline News
Dr Reddys Laboratories Up 13.0% Since SmarTrend Uptrend Call (RDY)
Comtex SmarTrend(R) - 1 hr 15 mins ago
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on October 23rd, 2014 at $50.46. In approximately 4 weeks, Dr Reddys Laboratories has returned 13.03% as of today's recent price of $57.03.
RDY: 56.98 (+0.20)
Dr. Reddy's Announces the Launch of Over-the-Counter Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets
Business Wire - 2 hrs 30 mins ago
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg, a bioequivalent generic version of Allegra-D(R) 12 Hour Allergy & Congestion, in the U.S. market on November 18, 2014. Dr. Reddy's ANDA is approved by the United States Food & Drug Administration (USFDA).
RDY: 56.98 (+0.20)
Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 3:30PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) and partner Takeda Pharmaceutical Company Limited filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Dr. Reddy's Laboratories (RDY).
JAZZ: 172.00 (+1.05), ARQL: 1.26 (-0.02), SCMP: 11.48 (-0.24), RDY: 56.98 (+0.20)
Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST
ENDP: 69.37 (+0.36), RDY: 56.98 (+0.20)
Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 4:20PM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, down 17% from the year-ago quarter.
MNK: 86.84 (+0.86), ACT: 264.02 (-2.02), MYL: 55.81 (+0.13), RDY: 56.98 (+0.20)
Dr. Reddy's Laboratories (RDY) Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 12:50AM CDT
RDY: 56.98 (+0.20)
Dr. Reddys ups revenues 7% in FQ2
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 12:43PM CDT
RDY: 56.98 (+0.20)
Dr. Reddy's FQ2 EPS of $0.54
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 5:55AM CDT
RDY: 56.98 (+0.20)
Dr. Reddy's Q2 and H1 FY15 Financial Results
Business Wire - Wed Oct 29, 5:41AM CDT
--Q2 FY15 EBITDA at Rs. 8.7 billion (24% of the revenues)
RDY: 56.98 (+0.20)
Dr. Reddy's Announces the Launch of Sirolimus Tablets, 1 mg and 2 mg
Business Wire - Tue Oct 28, 12:24PM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Sirolimus Tablets 1 mg and 2 mg, a therapeutic equivalent generic version of RAPAMUNE(R) (Sirolimus) tablets in the US market on October 27, 2014, following the approval by the United States Food & Drug Administration (USFDA).
RDY: 56.98 (+0.20)
Dr. Reddy's reports on October 29
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 6:09AM CDT
RDY: 56.98 (+0.20)
Dr. Reddy's to Release Q2 FY15 Results on October 29, 2014
Business Wire - Fri Oct 17, 4:38AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Second Quarter ended September 30, 2014 on Wednesday, October 29, 2014 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 56.98 (+0.20)
Sucampo Enters into Settlement Agreement for Amitiza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:50PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) has entered into a settlement agreement with Anchen and Par regarding a patent litigation related to Sucampo's Amitiza.
LCI: 47.15 (+0.31), SCMP: 11.49 (-0.23), RDY: 56.98 (+0.20)
Dr Reddys Laboratories Has Returned 20.3% Since SmarTrend Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 08, 4:57PM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 20.35% as of today's recent price of $49.92.
RDY: 56.98 (+0.20)
Dr Reddys Laboratories Shares Up 26.0% Since SmarTrend's Buy Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 01, 11:03AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 25.96% as of today's recent price of $52.25.
RDY: 56.98 (+0.20)
Dr. Reddy's (RDY) Generic Xopenex Launched in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:19PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) has launched its generic version of Sunovion Pharmaceuticals Inc.???s Xopenex in the U.S.
SUPN: 9.05 (+0.26), MYL: 55.81 (+0.13), TEVA: 57.26 (+0.01), RDY: 56.98 (+0.20)
Uptrend Call Working As Dr Reddys Laboratories Stock Rises 26.6% (RDY)
Comtex SmarTrend(R) - Wed Sep 24, 9:40AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 26.59% as of today's recent price of $52.51.
RDY: 56.98 (+0.20)
Dr. Reddy's unveils US FDA approved Levalbuterol Inhalation Solution, USP for oral inhalation only
M2 - Wed Sep 24, 7:03AM CDT
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Wednesday the market availability of Levalbuterol Inhalation Solution, USP 0.31 mg /3 ml, 0.63 mg /3 ml, 1.25 mg / 3 ml Unit-Dose Vials in the US.
RDY: 56.98 (+0.20)
Dr. Reddy's Announces the Launch of LEVALBUTEROL INHALATION SOLUTION, USP
Business Wire - Wed Sep 24, 2:27AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX(R) (levalbuterol hydrochloride) inhalation solution in the US market on September 23, 2014, approved by the United States Food & Drug Administration (USFDA).
RDY: 56.98 (+0.20)
